NCT04213807 - A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 11, 2019

Primary Completion Date

December 29, 2020

Study Completion Date

March 8, 2021

Conditions

Atrial Fibrillation

Interventions

BIOLOGICAL

MAA868 Cohort 1

Subcutaneous injection: low dose

BIOLOGICAL

MAA868 Cohort 2

Subcutaneous injection: high dose

BIOLOGICAL

MAA868 Cohort 3

Subcutaneous injection: Dose to be determined.

OTHER

Placebo

Subcutaneous injection: Placebo

Trial Locations (6)

Anthos Investigative Site, Wynnewood

Anthos Investigative Site, Lansing

Anthos Investigative Site, Wichita

Anthos Investigative Site, Alexandria

Anthos Investigative Site, McKinney

Anthos Investigative Site, Beverly Hills